Mediphase Venture Partners

Relypsa, Inc. is a biopharmaceutical company based in Redwood City, California, focused on the development and commercialization of innovative medicines for iron deficiency, nephrology, and cardio-renal conditions. Incorporated in 2007, Relypsa specializes in non-absorbed polymeric drugs, aiming to address medical needs in these therapeutic areas. Its flagship product, VELTASSA, is a potassium binder used in the treatment of hyperkalemia, a condition characterized by elevated potassium levels in the blood. The company targets overlooked and undertreated conditions that can be managed through gastrointestinal applications. As of late 2016, Relypsa operates as a subsidiary of Vifor Pharma Ltd.

Relypsa, Inc. is a biopharmaceutical company based in Redwood City, California, focused on the development and commercialization of innovative medicines for iron deficiency, nephrology, and cardio-renal conditions. Incorporated in 2007, Relypsa specializes in non-absorbed polymeric drugs, aiming to address medical needs in these therapeutic areas. Its flagship product, VELTASSA, is a potassium binder used in the treatment of hyperkalemia, a condition characterized by elevated potassium levels in the blood. The company targets overlooked and undertreated conditions that can be managed through gastrointestinal applications. As of late 2016, Relypsa operates as a subsidiary of Vifor Pharma Ltd.

Relypsa, Inc. is a biopharmaceutical company based in Redwood City, California, focused on the development and commercialization of innovative medicines for iron deficiency, nephrology, and cardio-renal conditions. Incorporated in 2007, Relypsa specializes in non-absorbed polymeric drugs, aiming to address medical needs in these therapeutic areas. Its flagship product, VELTASSA, is a potassium binder used in the treatment of hyperkalemia, a condition characterized by elevated potassium levels in the blood. The company targets overlooked and undertreated conditions that can be managed through gastrointestinal applications. As of late 2016, Relypsa operates as a subsidiary of Vifor Pharma Ltd.

Relypsa, Inc. is a biopharmaceutical company based in Redwood City, California, focused on the development and commercialization of innovative medicines for iron deficiency, nephrology, and cardio-renal conditions. Incorporated in 2007, Relypsa specializes in non-absorbed polymeric drugs, aiming to address medical needs in these therapeutic areas. Its flagship product, VELTASSA, is a potassium binder used in the treatment of hyperkalemia, a condition characterized by elevated potassium levels in the blood. The company targets overlooked and undertreated conditions that can be managed through gastrointestinal applications. As of late 2016, Relypsa operates as a subsidiary of Vifor Pharma Ltd.

Tetraphase Pharmaceuticals, Inc. is a biopharmaceutical company focused on the creation, development, and commercialization of innovative antibiotics aimed at treating serious and life-threatening multidrug-resistant infections. The company's primary product, Xerava, is a synthetic fluorocycline administered intravenously, designed as a first-line empiric monotherapy for multidrug-resistant infections, particularly those caused by MDR Gram-negative bacteria. Tetraphase has successfully conducted Phase III clinical trials for Xerava, specifically targeting complicated intra-abdominal infections. In addition to Xerava, the company is developing several other candidates, including TP-271 for respiratory diseases linked to bacterial biothreats and TP-6076 for MDR Gram-negative infections, both in Phase I clinical trials. Furthermore, TP-2846 is being explored as a treatment for acute myeloid leukemia. Tetraphase Pharmaceuticals has established a licensing agreement with Everest Medicines Limited to enhance the development and commercialization of Xerava in select regions across Asia. Founded in 2006 and headquartered in Watertown, Massachusetts, Tetraphase operates as a subsidiary of La Jolla Pharmaceutical Company.

ImpactRx, Inc. is a promotion research organization serving the pharmaceutical industry in the United States. The company specializes in tracking and evaluating the effects of pharmaceutical promotions on physicians' prescribing behaviors. Utilizing its proprietary technology, ImpactRx collects and processes data regarding physicians' perceptions and activities, enabling pharmaceutical companies to assess and predict the effectiveness of their sales and marketing initiatives. The organization offers a variety of syndicated and semi-custom products focused on brand management, market research, sales management, managed care marketing, and oncology sales and marketing. These services support pharmaceutical and biotech companies in making informed decisions. Founded in 2000, ImpactRx is headquartered in Mount Laurel, New Jersey.

Tetraphase Pharmaceuticals, Inc. is a biopharmaceutical company focused on the creation, development, and commercialization of innovative antibiotics aimed at treating serious and life-threatening multidrug-resistant infections. The company's primary product, Xerava, is a synthetic fluorocycline administered intravenously, designed as a first-line empiric monotherapy for multidrug-resistant infections, particularly those caused by MDR Gram-negative bacteria. Tetraphase has successfully conducted Phase III clinical trials for Xerava, specifically targeting complicated intra-abdominal infections. In addition to Xerava, the company is developing several other candidates, including TP-271 for respiratory diseases linked to bacterial biothreats and TP-6076 for MDR Gram-negative infections, both in Phase I clinical trials. Furthermore, TP-2846 is being explored as a treatment for acute myeloid leukemia. Tetraphase Pharmaceuticals has established a licensing agreement with Everest Medicines Limited to enhance the development and commercialization of Xerava in select regions across Asia. Founded in 2006 and headquartered in Watertown, Massachusetts, Tetraphase operates as a subsidiary of La Jolla Pharmaceutical Company.

Tetraphase Pharmaceuticals, Inc. is a biopharmaceutical company focused on the creation, development, and commercialization of innovative antibiotics aimed at treating serious and life-threatening multidrug-resistant infections. The company's primary product, Xerava, is a synthetic fluorocycline administered intravenously, designed as a first-line empiric monotherapy for multidrug-resistant infections, particularly those caused by MDR Gram-negative bacteria. Tetraphase has successfully conducted Phase III clinical trials for Xerava, specifically targeting complicated intra-abdominal infections. In addition to Xerava, the company is developing several other candidates, including TP-271 for respiratory diseases linked to bacterial biothreats and TP-6076 for MDR Gram-negative infections, both in Phase I clinical trials. Furthermore, TP-2846 is being explored as a treatment for acute myeloid leukemia. Tetraphase Pharmaceuticals has established a licensing agreement with Everest Medicines Limited to enhance the development and commercialization of Xerava in select regions across Asia. Founded in 2006 and headquartered in Watertown, Massachusetts, Tetraphase operates as a subsidiary of La Jolla Pharmaceutical Company.

Wellpartner is a prominent provider of pharmacy distribution solutions that serves health plans, Medicaid programs, and safety net organizations across the United States. The company specializes in managing 340B program services, focusing on innovative strategies that enhance pharmacy care while reducing medication costs. As the largest independent provider of contract pharmacy program services in the country, Wellpartner offers a range of services, including specialty pharmacy solutions and compliance support, aimed at maximizing the value of healthcare resources. By optimizing contract arrangements and ensuring access to specialty networks, Wellpartner helps healthcare organizations effectively serve more eligible patients and improve the overall quality of pharmacy care.

Concert Pharmaceuticals is a clinical‑stage biopharmaceutical company headquartered in Lexington, Massachusetts, founded in 2006. The company develops small‑molecule therapies for autoimmune and central nervous system disorders using a precision deuterium chemistry platform that modifies drug molecules to improve efficacy, safety, and reduce development risk. Its pipeline includes CTP‑543, a Phase III candidate for alopecia areata; CTP‑692, a Phase II candidate for schizophrenia; and AVP‑786, a Phase III combination therapy for neurologic and psychiatric conditions such as agitation in Alzheimer’s disease. Concert collaborates with Avanir, Cipla Technologies, Processa, and Jazz Pharmaceuticals to advance its candidates. The firm focuses on orally administered agents and repurposed drugs for conditions including cystic fibrosis, inflammation, narcolepsy, residual schizophrenia, major depressive disorder, and Alzheimer’s agitation.

Relypsa, Inc. is a biopharmaceutical company based in Redwood City, California, focused on the development and commercialization of innovative medicines for iron deficiency, nephrology, and cardio-renal conditions. Incorporated in 2007, Relypsa specializes in non-absorbed polymeric drugs, aiming to address medical needs in these therapeutic areas. Its flagship product, VELTASSA, is a potassium binder used in the treatment of hyperkalemia, a condition characterized by elevated potassium levels in the blood. The company targets overlooked and undertreated conditions that can be managed through gastrointestinal applications. As of late 2016, Relypsa operates as a subsidiary of Vifor Pharma Ltd.

Serenex is a U.S.-based medical drug discovery and development company established in 2000, specializing in oncology and related therapeutic areas. The company has developed a proprietary Hsp90 product platform, which includes a range of small molecule Hsp90 inhibitors targeting various conditions such as cancer, inflammatory diseases, fungal infections, viral diseases, and neurodegenerative disorders like Alzheimer's. Additionally, Serenex is advancing the development of SNX-1012, aimed at treating oral mucositis in patients with solid tumors. In 2008, Serenex was acquired by Pfizer, enhancing its capabilities in drug development and discovery.

Wellpartner is a prominent provider of pharmacy distribution solutions that serves health plans, Medicaid programs, and safety net organizations across the United States. The company specializes in managing 340B program services, focusing on innovative strategies that enhance pharmacy care while reducing medication costs. As the largest independent provider of contract pharmacy program services in the country, Wellpartner offers a range of services, including specialty pharmacy solutions and compliance support, aimed at maximizing the value of healthcare resources. By optimizing contract arrangements and ensuring access to specialty networks, Wellpartner helps healthcare organizations effectively serve more eligible patients and improve the overall quality of pharmacy care.

Tetraphase Pharmaceuticals, Inc. is a biopharmaceutical company focused on the creation, development, and commercialization of innovative antibiotics aimed at treating serious and life-threatening multidrug-resistant infections. The company's primary product, Xerava, is a synthetic fluorocycline administered intravenously, designed as a first-line empiric monotherapy for multidrug-resistant infections, particularly those caused by MDR Gram-negative bacteria. Tetraphase has successfully conducted Phase III clinical trials for Xerava, specifically targeting complicated intra-abdominal infections. In addition to Xerava, the company is developing several other candidates, including TP-271 for respiratory diseases linked to bacterial biothreats and TP-6076 for MDR Gram-negative infections, both in Phase I clinical trials. Furthermore, TP-2846 is being explored as a treatment for acute myeloid leukemia. Tetraphase Pharmaceuticals has established a licensing agreement with Everest Medicines Limited to enhance the development and commercialization of Xerava in select regions across Asia. Founded in 2006 and headquartered in Watertown, Massachusetts, Tetraphase operates as a subsidiary of La Jolla Pharmaceutical Company.

PatientKeeper is a company that specializes in developing EHR optimization software aimed at enhancing healthcare delivery. Its solutions are designed to streamline clinical and revenue cycle workflows for healthcare providers, care teams, billers, and coders, ultimately improving patient care and operational efficiency. PatientKeeper serves as a system of engagement that complements existing EHR systems, enabling providers to easily access and manage patient information across various devices, including smartphones, tablets, and PCs. The company’s applications allow physicians to efficiently handle patient data, view clinical results, enter diagnoses and billing information, dictate notes, and write prescriptions, thereby facilitating a more intuitive and effective approach to patient management.

Serenex is a U.S.-based medical drug discovery and development company established in 2000, specializing in oncology and related therapeutic areas. The company has developed a proprietary Hsp90 product platform, which includes a range of small molecule Hsp90 inhibitors targeting various conditions such as cancer, inflammatory diseases, fungal infections, viral diseases, and neurodegenerative disorders like Alzheimer's. Additionally, Serenex is advancing the development of SNX-1012, aimed at treating oral mucositis in patients with solid tumors. In 2008, Serenex was acquired by Pfizer, enhancing its capabilities in drug development and discovery.

Serenex is a U.S.-based medical drug discovery and development company established in 2000, specializing in oncology and related therapeutic areas. The company has developed a proprietary Hsp90 product platform, which includes a range of small molecule Hsp90 inhibitors targeting various conditions such as cancer, inflammatory diseases, fungal infections, viral diseases, and neurodegenerative disorders like Alzheimer's. Additionally, Serenex is advancing the development of SNX-1012, aimed at treating oral mucositis in patients with solid tumors. In 2008, Serenex was acquired by Pfizer, enhancing its capabilities in drug development and discovery.

Vitra Bioscience, a venture-backed biotechnology company, is developing novel technologies for comprehensive cellular analysis. The Company’s strategic objective is to create breakthrough solutions that enable users to acquire more informative data in less time, allowing for better decision-making. By applying modern imaging technology with proprietary consumables and software, Vitra Bioscience intends to develop and commercialize products that turn serial steps into parallel ones providing users with a complete tool set for their individual research needs.

PatientKeeper is a company that specializes in developing EHR optimization software aimed at enhancing healthcare delivery. Its solutions are designed to streamline clinical and revenue cycle workflows for healthcare providers, care teams, billers, and coders, ultimately improving patient care and operational efficiency. PatientKeeper serves as a system of engagement that complements existing EHR systems, enabling providers to easily access and manage patient information across various devices, including smartphones, tablets, and PCs. The company’s applications allow physicians to efficiently handle patient data, view clinical results, enter diagnoses and billing information, dictate notes, and write prescriptions, thereby facilitating a more intuitive and effective approach to patient management.

Serenex is a U.S.-based medical drug discovery and development company established in 2000, specializing in oncology and related therapeutic areas. The company has developed a proprietary Hsp90 product platform, which includes a range of small molecule Hsp90 inhibitors targeting various conditions such as cancer, inflammatory diseases, fungal infections, viral diseases, and neurodegenerative disorders like Alzheimer's. Additionally, Serenex is advancing the development of SNX-1012, aimed at treating oral mucositis in patients with solid tumors. In 2008, Serenex was acquired by Pfizer, enhancing its capabilities in drug development and discovery.

ImpactRx, Inc. is a promotion research organization serving the pharmaceutical industry in the United States. The company specializes in tracking and evaluating the effects of pharmaceutical promotions on physicians' prescribing behaviors. Utilizing its proprietary technology, ImpactRx collects and processes data regarding physicians' perceptions and activities, enabling pharmaceutical companies to assess and predict the effectiveness of their sales and marketing initiatives. The organization offers a variety of syndicated and semi-custom products focused on brand management, market research, sales management, managed care marketing, and oncology sales and marketing. These services support pharmaceutical and biotech companies in making informed decisions. Founded in 2000, ImpactRx is headquartered in Mount Laurel, New Jersey.

Serenex is a U.S.-based medical drug discovery and development company established in 2000, specializing in oncology and related therapeutic areas. The company has developed a proprietary Hsp90 product platform, which includes a range of small molecule Hsp90 inhibitors targeting various conditions such as cancer, inflammatory diseases, fungal infections, viral diseases, and neurodegenerative disorders like Alzheimer's. Additionally, Serenex is advancing the development of SNX-1012, aimed at treating oral mucositis in patients with solid tumors. In 2008, Serenex was acquired by Pfizer, enhancing its capabilities in drug development and discovery.

PatientKeeper is a company that specializes in developing EHR optimization software aimed at enhancing healthcare delivery. Its solutions are designed to streamline clinical and revenue cycle workflows for healthcare providers, care teams, billers, and coders, ultimately improving patient care and operational efficiency. PatientKeeper serves as a system of engagement that complements existing EHR systems, enabling providers to easily access and manage patient information across various devices, including smartphones, tablets, and PCs. The company’s applications allow physicians to efficiently handle patient data, view clinical results, enter diagnoses and billing information, dictate notes, and write prescriptions, thereby facilitating a more intuitive and effective approach to patient management.